Maternal smoking during pregnancy leads to increased risks of neonatal complications. The use of folic acid supplements might reduce the adverse effects of smoking. We examined whether folic acid supplement use modifies the associations of maternal smoking with first trimester plasma homocysteine concentrations, fetal growth characteristics, and risks of neonatal complications. The associations were studied in 6294 mothers participating in a prospective population-based cohort study in The Netherlands. Main outcomes measurements were first trimester plasma homocysteine concentrations, fetal growth characteristics, and neonatal complications, including preterm birth, low birth weight, and small-sizefor-gestational-age. Continued maternal smoking was associated with higher first trimester plasma homocysteine concentrations [difference 0.52 mmol/L (95% range = 0.20, 2.14)], lower third trimester fetal weight (difference 244 g (95% CI = 257, 231)], and birth weight [difference 2148 g (95% CI = 2179, 2118)]. There were significant interactions between maternal smoking and folic acid supplements on all outcome measures (all P-interaction , 0.040). Among mothers who continued smoking during pregnancy, those who did not use folic acid supplements had the highest risk of delivering a child with low birth weight [OR = 3.45 (95% CI = 1.25, 9.54)] compared to those who did use periconceptional folic acid supplements. No significant effects were observed for the risks of preterm birth and small-size-for-gestationalage at birth. Our results suggest that some adverse effects of maternal smoking on fetal growth and neonatal outcomes might be reduced by the use of folic acid supplements. The observed interaction seems to be mainly driven by smoking in the first trimester only.
Introduction
Impaired fetal growth is associated with neonatal morbidity and mortality (1) and risk of common diseases in later life such as type 2 diabetes and cardiovascular disease (2) (3) (4) . Maternal smoking is one of the most important causes of fetal growth retardation in Western countries. Previous studies showed that maternal smoking is associated with impaired fetal growth from early pregnancy onwards and increased risks of neonatal complications (5) (6) (7) . The mechanisms by which maternal smoking affects fetal growth include placental dysfunction, vasoconstriction, and hypoxia. Recently, it was shown that children exposed to maternal smoking have differences in global and gene-specific DNA methylation (8) , suggesting that smoking during pregnancy might also lead to epigenetic modifications in the offspring. These gene-specific DNA methylation alterations might lead to fetal and postnatal growth and development adaptations (9) . The use of folic acid supplements might be beneficial for the adverse effects of smoking on DNA methylation, because folate provides methyl groups for the synthesis of methionine. The derivate of methionine is an important methyl donor in the human body for DNA methylation (10) (11) (12) . We previously showed that folic acid supplement use is associated with increased fetal growth rates resulting in higher birth weight in the offspring (13) . Folate plays a critical role in homocysteine metabolism. The folate-dependent homocysteine pathway is important for protein, lipid, and DNA synthesis. Studies have shown that homocysteine concentrations are higher among smokers and lower among folic acid supplement users (14) (15) (16) (17) . Increased homocysteine concentrations are associated with alterations in birth weight (18) (19) (20) (21) . Based on these studies, we hypothesized that folic acid supplement use modifies the association between maternal smoking and fetal growth, potentially through altered homocysteine concentrations.
Therefore, we examined in an observational, populationbased, prospective cohort study among 6294 mothers and their children, whether folic acid supplement use modifies the associations of maternal smoking with first trimester plasma homocysteine concentrations, fetal growth characteristics, and the risk of neonatal complications, including preterm birth, low birth weight, and small-size-for-gestational-age at birth.
Participants and Methods
Design and cohort. This study was embedded in the Generation R Study, a population-based, prospective cohort study from early pregnancy onwards in Rotterdam, The Netherlands (22, 23) . All mothers were enrolled between 2001 and 2005. Of all eligible children in the study area, 61% participated at birth in the study (23) . The Medical Ethical Committee of the Erasmus Medical Center in Rotterdam approved the study (MEC 198.782/2001/31) . Written consent was obtained from all participating parents. Enrollment was aimed at early pregnancy (gestational age ,18.0 wk) but was allowed until delivery of the child. In total, 8880 women were enrolled in pregnancy (75% before gestational age of 18 wk). The median gestational age at enrollment was 14.4 wk (95% range = 10.2, 24.9). For this analysis, we excluded mothers without any information on smoking in each trimester or folic acid supplement use (n = 2396), and those without fetal ultrasound measurements (n = 84). Of the remaining 6400 mothers, we subsequently excluded those with induced abortion (n = 20), fetal or early neonatal death (n = 61), and loss to follow-up (n = 25). Thus, the total cohort for analysis comprised 6294 mothers (71% of 8880) (Supplemental Fig. 1 ).
Smoking during pregnancy. Information on smoking was obtained by self-administered questionnaires sent in the first, second, and third trimesters. Response rates for these questionnaires were 91, 80, and 77%, respectively (23) . Smoking at enrollment was assessed in the first questionnaire by asking each mother whether she smoked during pregnancy (no smoking; first trimester only smoking; still smoking). This questionnaire was sent to all mothers regardless of the gestational age at enrollment. To assess smoking habits in the second and third trimesters, mothers were asked whether they smoked in the past 2 mo (no or yes) in the second and third questionnaires. Mothers who reported in the first questionnaire that they smoked during the first trimester only but still reported smoking in the second or third questionnaire were reclassified into the "continued smoking" category. The same strategy was used for mothers who reported no smoking in the first questionnaire but reported smoking in the second or third questionnaire (5). Thus, both mothers who smoked during first, second, and third trimesters and those who reported to smoke during second and third trimesters were considered as continued smokers.
Folic acid supplement use. All mothers were asked by questionnaire at enrollment whether they had used a folic acid supplement periconceptionally (folic acid dosage of 0.4-0.5 mg/d, according to the advice of the Health Council of The Netherlands) and when supplement use started (24) . We categorized these mothers in the following group of folic acid supplementation uses: before pregnancy, during the first 10 wk of pregnancy, or no use. About 15% of the mothers reported to have used folic acid as part of a multivitamin supplement regimen. After repeating the analysis in mothers with folic supplement use only instead of the use of a multivitamin supplement, we found similar results (Supplemental Tables 1-3) . Self-reported folic acid supplement use was validated by plasma folate and homocysteine concentrations during the first trimester in a random subsample of the present study (n = 272). Details of the validation method were previously described (25) . Blood samples were collected between 7 and 12 wk of gestation. Within mothers who reported using folic acid supplements (n = 204; 75%), the median of serum folate was 23.5 nmol/L (95% CI = 4.3, 45.3), whereas the median serum folate concentration within mothers who did not use folic acid supplements (n = 68; 25%) was 11.1 nmol/L (95% CI = 4.7, 29.6). The difference was significant (P , 0.001, Mann-Whitney U test).
Plasma homocysteine concentrations. At enrollment in the first trimester, venous blood serum and plasma samples were drawn and thereafter stored for future use at 2808C (22) . Plasma homocysteine concentrations were analyzed using an immunoelectrochemiluminescence assay on the Architect System (Abbott Diagnostics) at the Department of Clinical Chemistry of the Erasmus Medical Center, Rotterdam in 2008. The between-run CV for plasma homocysteine were 3.1% at 7.6 mmol/L, 3.1% at 13.7 mmol/L, and 2.1% at 26.1 mmol/L. Plasma homocysteine concentrations in early pregnancy were available in 70% (n = 4432) of the study population. No differences in available smoking information were observed between mothers with and without known plasma homocysteine concentrations.
Fetal growth characteristics. Fetal ultrasound examinations were carried out in two dedicated research centers in each trimester of pregnancy. We established gestational age by first trimester fetal ultrasound examination (26) . In the second and third trimesters of pregnancy, we measured parameters of head circumference, abdominal circumference, and femur length to the nearest millimeter using standardized ultrasound procedures, which were previously described in detail (26, 27) . The estimated fetal weight was subsequently calculated using the formula by Hadlock et al. (28) . Gestational age-adjusted SD scores were constructed for all fetal growth measurements. These gestational age-adjusted SD scores were based on reference growth curves from the complete study population and represent the equivalent Z-scores (26) . We used our own study population to construct the curves, because longitudinal data on these fetal growth characteristics were not available in a similar population-based cohort in The Netherlands.
Neonatal complications. Low birth weight was defined as birth weight ,2500 g, independent of the gestational age at birth. Small-size-forgestational-age at birth was defined as a gestational age-adjusted birth weight lower than the 5th percentile in the study cohort, and preterm birth was defined as gestational age of ,37 wk at delivery.
Covariates. Information on maternal age at enrollment (continuous), highest completed educational level (primary school, secondary school, higher education), ethnicity (European, non-European), and parity (nulliparous, multiparous) was obtained from the first questionnaire at enrollment in the study. Height (cm) and weight (kg) at enrollment were measured without shoes and heavy clothing. Weight was repeatedly measured during subsequent visits at the research center. BMI at early gestation was calculated from maternal weight and maternal height [weight/height 2 (kg/m 2 )] (29). Maternal weight measured at enrollment in the study was strongly correlated with prepregnancy weight (r = 0.95; P , 0.01). We used maternal weight measured at enrollment to calculate maternal BMI, because the numbers of missing values were smaller and data quality higher than the prepregnancy weight, which was reported by the mother in a self-administered questionnaire (30) . Alcohol consumption (none, first trimester only, continued) and caffeine intake (,2.0 units/d, 2.0-3.9 units/d, .4.0 units/d) were assessed in each questionnaire. One unit of caffeine is the equivalent of 70 mg of caffeine (31) . We used the same strategy to classify mothers in either the nonalcohol consuming category, first trimester only, or continued alcohol consumption as we used for smoking status. First trimester total daily energy intake was assessed at enrollment using a slightly adapted version of the validated FFQ of Klipstein-Grobusch et al. (29, 32, 33) . Details of the FFQ were previously described in more detail (34) . Maternal distress (continuous) was measured by questionnaire at 20 wk of gestation using the Brief Symptom Inventory, which measures distress in the general population and yields a Global Severity Index (35) . A higher Global Severity Index reflects a more stressful maternal experience.
Statistical analyses. Differences in maternal characteristics between maternal smoking and folic acid supplement use groups were expressed
Smoking, folic acid, and neonatal complications 2173 as means 6 SD, percentages, or median (95% range) and tested using 1-way ANOVA for continuous variables and chi-square tests for categorical variables. First, the associations of smoking habits and folic acid supplement use with first trimester plasma homocysteine concentrations were analyzed using multiple linear regression models. We applied log transformation and presented effect estimates as geometric means to improve interpretation of the results, because plasma homocysteine concentrations were not normally distributed. For this analysis, we combined first trimester only smoking and continued smoking mothers into one group of mothers who smoked in the first trimester. Second, we analyzed the associations of smoking habits and folic acid supplement use with second and third trimester measured estimated fetal weight and birth weight using multiple linear regression models. Third, the associations of smoking and folic acid supplement categories with neonatal complications (preterm birth, low birth weight, small-size-for-gestationalage at birth) were assessed using multiple logistic regression models. For all analyses, we tested the interaction between smoking and folic acid supplement use. All models were adjusted for gestational age at the visit or at birth, maternal age, BMI at enrollment, educational level, parity, ethnicity, alcohol consumption, caffeine intake, total energy intake, maternal stress, and fetal sex. Covariates were included based on previous studies, their strong association with the outcome, or change in effect estimates. The percentages of missing values within the population for analysis were ,4%, except for total energy intake (23%) and maternal stress (20%). These higher percentages were due the large number of mothers who only partially completed the FFQ or were enrolled later in pregnancy. Missing data in the covariates were imputed using the multiple imputation procedure, which is used to select the most likely value for a missing response (36) . Five imputed data sets were created and analyzed together. No differences in results were observed between analyses with imputed missing data or complete cases only. We only present the results based on imputed datasets. Significance was set at P , 0.05. The analyses were performed using the SPSS version 17.0 for Windows.
Results
Of the total of 6294 mothers, 16.8% (n = 1059) continued smoking during pregnancy and 29.3% (n = 1846) did not use folic acid supplements ( Table 1) . Children of smoking mothers and mothers who did not use folic acid supplements were born more frequently with a low birth weight and small-size-forgestational-age at birth (Supplemental Tables 4 and 5) .
Mothers who smoked during pregnancy had higher first trimester plasma homocysteine concentrations compared to those who did not smoke [geometric means of 7.44 mmol/L (95% range = 4.80, 13.8) and 6.92 mmol/L (95% range = 4.60, 11.7), respectively] (Supplemental Table 6 ). Among both nonsmoking and smoking mothers, no folic acid supplement use or use in the first trimester only was associated with higher plasma homocysteine concentrations (all P , 0.01). There was an interaction between maternal smoking and folic acid supplement use (P-interaction , 0.001) ( Table 2) . After repeating the analyses restricted to mothers who reported smoking from the first trimester onwards (excluding mothers who reported smoking in the second and third trimesters only), we observed similar results (data not shown).
There was an interaction between maternal smoking and folic acid supplement use on second (P-interaction = 0.040) and third trimester (P-interaction ,0.001) estimated fetal weight (Supplemental Table 7 ). However, we did find a stronger effect of interaction with folic acid supplement use on birth weight (both P-interaction ,0.001) compared to second and third trimester estimated fetal weight. We observed, within each smoking stratum, a lower birth weight among children of mothers who did not use folic acid supplements compared to children of Table 3) . Mothers who continued smoking during pregnancy and did not use folic acid supplements had the greatest decrease in third trimester estimated fetal weight and birth weight compared to mothers who did not smoke during pregnancy and used periconceptional folic acid supplements (Table 3 ; Fig. 1 ).
Continued maternal smoking was associated with increased risks of preterm birth, low birth weight, and small-sizefor-gestational-age at birth (Supplemental Table 8 ). For all 3 outcomes, these associations were modified by folic acid supplement use (P-interaction = 0.023 for preterm birth; Pinteraction ,0.01 for low birth weight; and P-interaction ,0.001 for small-size-for-gestational-age at birth). Mothers who continued smoking during pregnancy and who did not use folic acid supplements had the highest risk of low birth weight [OR = 3.45 (95% CI = 1.25, 9.54)] compared to those who did use periconceptional folic acid supplements. No significant effects were found on the risks of preterm birth [OR = 1.82 (95% CI = 0.82, 4.02)] and small-size-forgestational-age at birth [OR = 1.29 (95% CI = 0.69, 2.42)]. Overall, mothers who continued smoking and did not use folic acid supplements had the highest risks of low birth weight [OR = 3.24 (95% CI = 1.71, 6.13)] and small-size-for-gestationalage at birth [OR = 3.19 (95% CI = 2.02, 5.04)] compared to mothers who did not smoke and used periconceptional folic acid supplements ( Table 4) .
Discussion
Results from this observational, prospective, population-based cohort study suggest interaction of periconceptional folic acid supplement and maternal smoking during pregnancy on fetal growth throughout pregnancy. We observed that the adverse effects of maternal smoking on first trimester plasma homocysteine concentrations and the risk of low birth weight might be reduced by the use of folic acid supplements. All significant interactions were mainly driven by smoking in first trimester only.
Methodological considerations. This study is based on a prospective data collection, which started in early pregnancy. We had a large sample size of 6294 participants and a wide range of potential confounding factors available. A potential limitation of our study is that smoking and folic acid supplement use information was not available for all pregnant mothers, which might have led to loss of power. No differences in characteristics between mothers with and without information about smoking habits and folic acid supplement use were observed. Among mothers with information about smoking habits and folic acid supplements use, we had a limited loss to follow-up. Therefore, we do not expect biased results due to loss to follow-up (37) . Another possible limitation is that information on smoking and folic acid supplement use during pregnancy was collected by questionnaires. Although assessing smoking and folic acid supplement use during pregnancy by questionnaire seems to be valid method, misclassification may have occurred, which may have led to underreporting of smoking status and a subsequent underestimation of our effect estimates (38, 39) . Previous studies have used biomarkers of tobacco exposure, including cotinine, in maternal urine samples (40, 41) . However, low correlations between cotinine concentrations and self-reported smoking habits have been demonstrated (42) . Most importantly, we used data from an observational design. As in all observational studies, especially focused on an intervention, residual confounding might be an important issue. Although we were able to adjust for multiple potential confounders, our results should be considered as hypothesis generating and ideally need confirmation from randomized controlled trials. Because folic acid supplement use is strongly advised for all pregnant women in The Netherlands, we cannot perform such a study in The Netherlands.
Modification of folic acid supplement use. We hypothesized that folic acid supplement use modifies the association between maternal smoking and fetal growth. Many studies have suggested that maternal smoking is associated with impaired fetal growth and increased risk of neonatal complications (6, (43) (44) (45) . Birth weight is 150-250 g lower among children of mothers who continued smoking during pregnancy (6, 43) . We previously found reduced fetal growth in different growth parameters throughout pregnancy (5) and increased risks of low birth weight and preterm birth (46) among mothers who continued smoking during pregnancy. Furthermore, fetal growth retardation due to smoking of the mother is suggested to occur already in the first trimester (7). It has been suggested that increased nicotine concentration in the blood of the smoking mother (47) leads to constriction of the uterine blood vessels and thereby decreases the blood flow to the placenta (48) , which may lead to impaired feto-placental perfusion and decreased oxygen and nutrient transfer across the placenta, resulting in fetal growth retardation (49) . Recently, Breton et al. (8) showed that children exposed to smoking have differences in global and gene-specific DNA methylation. This suggests that maternal smoking might also lead to epigenetic modifications in the offspring starting in utero. These gene-specific DNA methylation alterations may lead to alterations of fetal and postnatal growth and development (9) . The adverse effects of maternal smoking on DNA methylation in the offspring might be influenced by folic acid supplement use. Folate provides methyl groups for the methionine synthesis. The derivate of methionine is an important Curves are based on SD scores of second trimester estimated fetal weight (n = 3795), third trimester estimated fetal weight (n = 3901), and birth weight (n = 4031). Mothers who smoked during the first trimester only and mothers who used folic acid supplements in the first trimester only were excluded from this analysis. Estimates are given for mothers who did not smoke and did not use folic acid supplements, and mothers who continued smoking and used periconceptional folic acid supplements or no folic acid supplements. *P , 0.05; **P , 0.01.
methyl donor for DNA methylation (10) (11) (12) . Accordingly, we previously showed that folic acid supplement use is associated with increased fetal growth rates resulting in higher birth weight in the offspring (13) . Furthermore, folate plays a critical role in homocysteine metabolism. The folate-dependent homocysteine pathway is important for protein, lipid, and DNA synthesis.
Previous studies and also this study show that homocysteine concentrations are higher among smokers and lower among folic acid supplement users (14) (15) (16) (17) . Our results show lower concentrations of plasma homocysteine among smoking mothers who did use folic acid supplements compared to smoking mothers who did not use folic acid supplements. We found reduced effects of maternal smoking on weight at birth among mothers who used folic acid supplements. The effect estimates of overall differences were slightly different from the effect estimates given per smoking strata. This is due to the use of different reference groups in the analyses. Pregnant women are advised to use folic acid supplements until wk 12 of their pregnancy, but we are not sure when exactly they ended the supplementation. The stronger effects found in the third trimester and at birth (P-interaction , 0.001) might be the result of changes during embryonic growth or successful early placentation, because folic acid supplements were used during the early stages of pregnancy only (7, 50) . Also, a similar modifying effect of folic acid supplement use was found for the association between maternal smoking and the risk of low birth weight. Overall, the beneficial effects of folic acid supplement use on fetal growth and neonatal outcomes were stronger among mothers who smoked during pregnancy compared to those who did not smoke. Recently, Mook-Kanamori et al. (7) showed similar results in early pregnancy. Furthermore, a study of Suter et al. (51) emphasized that not all fetuses experience similar adverse outcomes as a result of environmental exposures such as tobacco. There might to be a potential genetic and metabolic susceptibility for the environmental exposures on adverse birth outcomes. Folic acid may play an important role in altering this genetic susceptibility for smoking exposure of the fetus on subsequent impaired growth in utero.
In conclusion, our results suggest that the adverse effects of maternal smoking on first trimester plasma homocysteine concentrations, birth weight, and the risk of low birth weight might be reduced by the use of folic acid supplements. The observed interaction was mainly driven by smoking in the first trimester only. Although our findings might be of important public health relevance, they should be interpreted carefully because of the observational design.
